Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2001

View Archived Issues

Licensing opportunity from NIH: analogues of thalidomide as potential angiogenesis inhibitors

NIH licensing opportunity: methods and compositions for inhibiting HIV-coreceptor interactions

Antiinfluenza activity of BioCryst's cyclopentane neuraminidase inhibitor studied

Introgen's INGN-241 demonstrates potent antitumor properties in preclinical studies

Avant initiates second phase IIb trial of TP-10 in infants

Xenova reports Q1 highlights; merger with Cantab completed

Postprandial TG-lowering effects of NK-104 investigated in animal model

FM-VP4 highlighted at recent AHA conference as novel therapy for cardiovascular disease

Active metabolite of leflunomide proven to suppress eotaxin production

Therapeutic pipeline update provided by BioChem Pharma

Cannabinoid receptor agonist reduces IOP in monkeys with and without glaucoma

GSK designs and characterizes a new, high-affinity, selective PPARdelta agonist

Baxter seeks FDA approval to evaluate Neuprex for Crohn's disease

FDA clears phase II trials of novel immunosuppressive drug

Independent DSMB recommends continuation of phase III Theratope trial

Polypeptide with potential in gene therapy for immunodeficiency discovered at Hayashibara

Safety of mitoxantrone in MS patients highlighted at AAN meeting

Durect completes clinical portion of DUROS sufentanil phase II trial

MCH antagonists and use in obesity disclosed by Takeda

Potent and selective alpha1-adrenoceptor ligands reported by Lundbeck

Bivalent FVIIa/TF/FXa complex inhibitors

Shionogi prepares and tests new CB2 receptor ligands

Prostaglandin derivatives claimed by Taisho for inducing sleep, Rx of renal and cardiac disorders

Inhibitors of protein prenyltransferases identified by Dutch researchers

Company Profile: Conforma Therapeutics

NicOx nitric oxide-releasing steroid shows no blanching effect in phase I

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.